Please login to the form below

Not currently logged in

Nycomed in BT HP deal

Nycomed has signed a new five-year communications and IT deal with BT and Hewlett Packard to outsource its infrastructure
Nycomed has signed a new five-year communications and IT deal with BT and Hewlett Packard (HP) to outsource its infrastructure.

Swiss pharmaceutical company Nycomed choose the BT HP alliance to manage over 450 of its servers and 10,000 workstations across 50 countries. Nycomed's technology infrastructure will be outsourced to BT and HP to help facilitate rapid dissemination of information critical to the company.

Agnetha Mattisson, senior vice-president of corporate IS/IT for the privately owned pharma company, said: "Together we will establish a robust and scalable environment that will support Nycomed's goals to grow the business."

"Nycomed is taking advantage of the BT HP alliance's economies of scale, skilled staff and industrialisation of operations," Mattisson added.

Ann Livermore, executive vice president of technology solutions group for HP, said: "We are honoured to be selected by Nycomed as a trusted partner and we look forward to helping them manage and transform their infrastructure into an asset for business and competitive advantage."

Nycomed's presence in approximately 50 markets globally and its acquisition of German based Atlanta Pharma in 2007 makes it one of the 25 largest pharmaceutical companies in the world.

9th April 2008


Featured jobs

Subscribe to our email news alerts


Add my company

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...